GKOS logo

GKOS
Glaukos Corporation

914
Mkt Cap
$7.11B
Volume
455,022.00
52W High
$130.23
52W Low
$73.16
PE Ratio
-37.14
GKOS Fundamentals
Price
$121.48
Prev Close
$120.87
Open
$121.10
50D MA
$112.95
Beta
1.26
Avg. Volume
722,460.75
EPS (Annual)
-$3.28
P/B
10.65
Rev/Employee
$463,840.95
$6,285.11
Loading...
Loading...
News
all
press releases
Glaukos (GKOS) Expected to Announce Earnings on Wednesday
Glaukos (NYSE:GKOS) will be releasing its Q1 2026 earnings after the market closes on Wednesday, April 29. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-29-glaukos-co-stock...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy
GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.
Zacks·11d ago
News Placeholder
Glaukos Announces the Release of its 2025 Sustainability Report
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today...
Business Wire·11d ago
News Placeholder
Glaukos Receives Permanent J-code for Epioxa
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases...
Business Wire·12d ago
News Placeholder
Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of "Moderate Buy" by Analysts
Glaukos Corporation (NYSE:GKOS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the sixteen research firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold...
MarketBeat·13d ago
News Placeholder
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans...
Business Wire·19d ago
News Placeholder
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases...
Business Wire·21d ago
News Placeholder
Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS
Capricorn Fund Managers Ltd bought a new stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·21d ago
News Placeholder
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC lifted its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 32.8% during the 4th quarter, according to its most recent filing with the...
MarketBeat·24d ago
News Placeholder
SG Americas Securities LLC Purchases 49,492 Shares of Glaukos Corporation $GKOS
SG Americas Securities LLC boosted its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 460.8% during the 4th quarter, according to its most recent 13F filing with the...
MarketBeat·26d ago
<
1
2
...
>

Latest GKOS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.